Journal
INTERNATIONAL JOURNAL OF POLYMERIC MATERIALS AND POLYMERIC BIOMATERIALS
Volume 67, Issue 18, Pages 1105-1115Publisher
TAYLOR & FRANCIS AS
DOI: 10.1080/00914037.2018.1429434
Keywords
Hepatocellular carcinoma improved bioavailability; nanoparticles; sorafenib
Categories
Ask authors/readers for more resources
Sorafenib is the only approved targeted agent against hepatocellular carcinoma (HCC). It has several limitations predominantly poor aqueous solubility and hepatic first-pass effect that limits its oral delivery leading to low bioavailability, large inter-subject variability, narrow therapeutic window and side effects. Tosylate is used to improve its solubility, which is practically insoluble in water (60 mu g/mL) so problems with sorafenib solubility persist. To improve the paharmacokinetic profile, minimize the side effects, and targeting drug to the tumor tissues, several polymeric nano-formulations are being evaluated. In this comprehensive review, various reported polymeric nano-delivery systems for sorafenib are comprehensively covered. [GRAPHICS] .
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available